Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates

Antiviral Research
Eugenia Z OngEng Eong Ooi

Abstract

Despite useful in vivo activity, no therapeutic against dengue virus (DENV) has demonstrated efficacy in clinical trials. Herein, we explored dosing and virological endpoints to guide the design of human trials of VIS513, a pan-serotype anti-DENV IgG1 antibody, in non-human primates (NHPs). Dosing VIS513 pre- or post-peak viremia in NHPs neutralized infectious DENV although RNAemia remained detectable post-treatment; differential interaction of human IgGs with macaque Fc-gamma receptors may delay clearance of neutralized DENV. Our findings suggest useful antiviral utility of VIS513 and highlight an important consideration when evaluating virological endpoints of trials for anti-DENV biologics.

Citations

Jan 31, 2020·PLoS Neglected Tropical Diseases·Rob Hooft van HuijsduijnenKei Katsuno
Feb 27, 2020·Reviews in Medical Virology·Arianna Mahely Hurtado-MonzónRosa María Del Ángel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Ichiro Kurane
Nihon rinsho. Japanese journal of clinical medicine
Tomohiko Takasaki
© 2022 Meta ULC. All rights reserved